Molecular Templates
Molecular Templates develops novel therapeutic compounds for cancer.
Employees
Market cap
$7.5m
Enterprise valuation
$6m (Public information from Sep 2024)
Share price
$1.34 MTEM
Georgetown Texas (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 19.5m | 15.6m | 38.7m | 19.8m | 52.6m | 12.3m | 1.3m |
| % growth | - | (20 %) | 148 % | (49 %) | 166 % | (77 %) | (90 %) |
| EBITDA | (46.0m) | (99.8m) | (80.1m) | (87.9m) | (2.6m) | - | - |
| % EBITDA margin | (236 %) | (638 %) | (207 %) | (445 %) | (5 %) | - | - |
| Profit | (69.4m) | (105m) | (83.0m) | (92.7m) | (8.1m) | (21.3m) | (33.4m) |
| % profit margin | (356 %) | (671 %) | (215 %) | (469 %) | (15 %) | (173 %) | (2654 %) |
| EV / revenue | 36.3x | 25.0x | 2.9x | 0.9x | 0.4x | 0.8x | 8.0x |
| EV / EBITDA | -15.4x | -3.9x | -1.4x | -0.2x | -7.7x | - | - |
| R&D budget | 50.5m | 93.0m | 84.7m | 82.4m | 48.9m | - | - |
| R&D % of revenue | 259 % | 595 % | 219 % | 417 % | 93 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$2.5m | Series A | ||
$1.4m | Early VC | ||
| N/A | $10.6m | Grant | |
$7.0m | Early VC | ||
$3.5m | Series C | ||
N/A | Series D | ||
| N/A | N/A | IPO | |
$60.0m | Post IPO Equity | ||
* | $9.5m | Private Placement VC | |
| Total Funding | $34.5m | ||
Related Content
Recent News about Molecular Templates
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Molecular Templates
Edit
ACQUISITION by Molecular Templates Aug 2017